Abstract
The discovery of (±)-epibatidine, a naturally occurring neuronal nicotinic acetylcholine receptor (nAChR) agonist with antinociceptive activity 200-fold more potent than that of morphine, has renewed interest in the potential role of nAChRs in pain processing. However, (±)-epibatidine has significant side-effect liabilities associated with potent activity at the ganglionic and neuromuscular junction nAChR subtypes which limit its potential as a clinical entity. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] is a novel, potent cholinergic nAChR ligand with analgesic properties (see accompanying paper by Bannon et al., 1998b) that shows preferential selectivity for neuronal nAChRs and a consequently improved in vivo side-effect profile compared with (±)-epibatidine. ABT-594 is a potent inhibitor of the binding of [3H](−)-cytisine to α4β2 neuronal nAChRs (Ki = 37 pM, rat brain;Ki = 55 pM, transfected human receptor). At the α1β1δγ neuromuscular nAChR labeled by [125I]α-bungarotoxin (α-Btx), ABT-594 has aKi value of 10,000 nM resulting in a greater than 180,000-fold selectivity of the compound for the neuronal α4β2 nAChR. In contrast, (±)-epibatidine has Kivalues of 70 pM and 2.7 nM at the α4β2 and α1β1δγ nAChRs, respectively, giving a selectivity of only 38-fold. TheS-enantiomer of ABT-594, A-98593 has activity at the neuronal α4β2 nAChR identical with ABT-594 (Ki = 34–39 pM), which demonstrates a lack of stereospecific binding similar to that reported previously for (±)-epibatidine. A similar lack of stereoselectivity is seen at the human α7 receptor. However, A-98593 is 3-fold more potent at the neuromuscular nAChR (Ki = 3420 nM) and the brain α-Btx-sensitive nAChR (Ki = 4620 nM) than ABT-594. ABT-594 has weak affinity in binding assays for adrenoreceptor subtypes alpha-1B (Ki = 890 nM), alpha-2B (Ki = 597 nM) and alpha-2C (Ki = 342 nM), and it has negligible affinity (Ki > 1000 nM) for approximately 70 other receptors, enzyme and transporter binding sites. Functionally, ABT-594 is an agonist. At the transfected human α4β2 neuronal nAChR (K177 cells), with increased 86Rb+ efflux as a measure of cation efflux, ABT-594 had an EC50 value of 140 nM with an intrinsic activity (IA) compared with (−)-nicotine of 130%; at the nAChR subtype expressed in IMR-32 cells (sympathetic ganglion-like), an EC50 of 340 nM (IA = 126%); at the F11 dorsal root ganglion cell line (sensory ganglion-like), an EC50 of 1220 nM (IA = 71%); and viadirect measurement of ion currents, an EC50 value of 56,000 nM (IA = 83%) at the human α7 homo-oligimeric nAChR produced in oocytes. A-98593 is 2- to 3-fold more potent and displays approximately 50% greater intrinsic activity than ABT-594 in all four functional assays. In terms of potency, ABT-594 is 8- to 64-fold less active than (±)-epibatidine and also has less IA in these functional assays. ABT-594 (30 μM) inhibits the release of calcitonin gene-related peptide from C-fibers terminating in the dorsal horn of the spinal cord, an effect mediated via nAChRs. Pharmacologically, ABT-594 has an in vitro profile distinct from that of the prototypic nicotinic analgesic (±)-epibatidine, with the potential for substantially reduced side-effect liability and, as such, represents a potentially novel therapeutic approach to pain management.
Footnotes
-
Send reprint requests to: Diana L. Donnelly-Roberts, Ph.D., NUDR, Building AP10, Dept. 47W, Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064-3500.
- Abbreviations:
- capsaicin
- 8-methyl-N-vanillyl-6-nonenamide
- nAChR
- nicotinic acetylcholine receptor
- ACh
- acetylcholine
- α-Btx
- α-bungarotoxin
- FLIPR
- fluorescence imaging plate reader
- CGRP-LI
- calcitonin gene-related peptide-like immunoreactivity
- DRG
- dorsal root ganglion
- GABA
- γ-aminobutyric acid
- HEPES
- N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
- Received September 12, 1997.
- Accepted January 13, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|